Shinpoong Pharmaceutical Co.,Ltd (KRX:019170)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,090
+1,250 (14.14%)
At close: Aug 28, 2026

KRX:019170 Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
239,065234,681221,094200,229209,288189,237
Other Revenue
0----0-
239,065234,681221,094200,229209,288189,237
Revenue Growth
6.21%6.14%10.42%-4.33%10.60%-4.30%
Cost of Revenue
136,964132,010139,290119,951131,315111,850
Gross Profit
102,102102,67181,80480,27777,97377,388
Selling, General & Admin
86,06176,93977,76479,06876,54969,256
Research & Development
11,23610,44317,87942,27730,38317,334
Amortization of Goodwill & Intangibles
507.46540.74969.421,1821,3581,496
Other Operating Expenses
94.8-143.43800.65394.37646.983,241
Operating Expenses
99,41088,41698,833127,670111,99291,694
Operating Income
2,69214,255-17,029-47,392-34,019-14,306
Interest Expense
-3,034-2,688-2,632-1,719-61.42-202.06
Interest & Investment Income
1,087767.26704.061,1741,0261,878
Earnings From Equity Investments
----6,514-697.092,620
Currency Exchange Gain (Loss)
2,086-1,2322,8331,328-1,009406.81
Other Non Operating Income (Expenses)
84.63167.43279.23653.36-182.48314.91
EBT Excluding Unusual Items
2,91611,269-15,844-52,471-34,942-9,288
Gain (Loss) on Sale of Investments
-2,932-2,8201,215-1,011845.62253.64
Gain (Loss) on Sale of Assets
21.082.546.8939.6518.3149.02
Asset Writedown
-----703.23-
Pretax Income
5.658,452-14,622-53,442-34,782-8,986
Income Tax Expense
752.1762.48751.413,831527.292,540
Earnings From Continuing Operations
-746.528,389-15,373-57,273-35,309-11,526
Minority Interest in Earnings
-68.76435.95-13.8-52.86-68.14-57.61
Net Income
-815.288,825-15,387-57,325-35,377-11,584
Preferred Dividends & Other Adjustments
371.51371.51----
Net Income to Common
-1,1878,454-15,387-57,325-35,377-11,584
Net Income Growth
------
Shares Outstanding (Basic)
504951515151
Shares Outstanding (Diluted)
504951515151
Shares Change
23.67%-3.62%-0.28%--1.85%
EPS (Basic)
-23.95171.57-301.00-1118.28-690.12-225.97
EPS (Diluted)
-23.95171.57-301.00-1118.28-690.12-225.97
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
13,57413,776-20,724-39,696-31,767-75,453
Free Cash Flow Per Share
273.98279.60-405.39-774.37-619.69-1471.90
Gross Margin
42.71%43.75%37.00%40.09%37.26%40.89%
Operating Margin
1.13%6.07%-7.70%-23.67%-16.25%-7.56%
Profit Margin
-0.50%3.60%-6.96%-28.63%-16.90%-6.12%
Free Cash Flow Margin
5.68%5.87%-9.37%-19.82%-15.18%-39.87%
EBITDA
14,00825,648-5,066-35,484-21,215-1,631
EBITDA Margin
5.86%10.93%-2.29%-17.72%-10.14%-0.86%
D&A For EBITDA
11,31611,39311,96311,90812,80312,675
EBIT
2,69214,255-17,029-47,392-34,019-14,306
EBIT Margin
1.13%6.07%-7.70%-23.67%-16.25%-7.56%
Effective Tax Rate
13304.74%0.74%----
Advertising Expenses
-11,85516,98117,97919,12617,097